VCIM
EPRX

Velan Capital Investment Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Velan Capital Investment Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.55M Hold
352,000
– – 1.6% 16
2025
Q4 		$2.66M Hold
352,000
– – 1.54% 20
2025
Q3 		$2.08M Buy
+352,000
New +$1.92M 1.95% 15

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Velan Capital Investment Management's EPRX Position: Q1 2026 in Review

Velan Capital Investment Management held its Eupraxia Pharmaceuticals (EPRX) position steady in Q1 2026 at 352,000 shares worth $2.55M. The position accounts for 1.6% of the portfolio, ranked #16.

Velan Capital Investment Management first reported a position in EPRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.66M in Q4 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Velan Capital Investment Management held 352,000 shares of Eupraxia Pharmaceuticals worth $2.55M as of Q1 2026.
  • Velan Capital Investment Management left its Eupraxia Pharmaceuticals share count unchanged in Q1 2026.
  • Eupraxia Pharmaceuticals made up 1.6% of Velan Capital Investment Management's portfolio in Q1 2026, its #16 holding.
  • Velan Capital Investment Management first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Velan Capital Investment Management's Eupraxia Pharmaceuticals position peaked at $2.66M in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.